Browsing by Author "Ashenafi Girma"

Now showing 1 - 1 of 1
  • No Thumbnail Available
    Item
    Assessment of Immunohematological Outcome Among Adult HIV Patients Taking Highly Active Antiretroviral Therapy for at Least Six Months in Yabelo Hospital, south East Ethiopia.
    (Addis Abeba University, 2021-10) Ashenafi Girma; Tsegaye Aster ; Tibebu Melatwork
    Background: Immunohematological parameters are key tools for evaluating antiretroviraltreatment and prognosis during follow up in Human immunodeficiency virus infectedpatients. Clinical response to highly active antiretroviral therapy in resource-limited settingsis monitored with CD4 + T cell counts and some hematologic indices. Comparing baselineimmunohematological parameters of infected patients with their change after they taketreatment for at least six months is very useful in evaluating treatment success. Objective: To assess changes in immunological and haematological parameters in HIVinfected patients on HAART for at least Six months at the antiretroviral therapy clinic ofYabelo Hospital, Borena, Ethiopia. Methods: A cross sectional study was conducted from February to July 2021 usingconvenient sampling method to recruit 333 HIV infected adults who were on follow-up for atleast six months at the ART clinic of Yabelo hospital. Socio-demographic and clinicalcharacteristics data were collected using pre-tested structured questionnaire. Venous bloodsamples were collected and processed following standard procedures for determining CD4+T cell count and complete blood count using FACSPresto and Sysmex XE 2100 automatedhaematology analyser, respectively. Data analysis was performed using SPSS version 25.Bivariate and multivariable analyses were conducted to identify factors significantlyassociated with the outcome variable. P –value < 0.05 was considered as significant. Result:- The prevalence of anemia(47.4%),leucopenia(73.3%),neutropenia (58.3%),lymphopenia (76.9% ) and thrombocytopenia(3.3% ) before starting of highly activeantiretroviral therapy was declined to 23.1%, 36.4%, 23.4%, 35.7% and 2.4% after initiationof highly active antiretroviral therapy, respectively; there was also significant decrease in therate of Immunosuppression (62.2% to 20.7%). Except MCHC, there was a significantimprovement in the common hematological parameters after use of highly activeantiretroviral therapy for at least six month.Treatment interruption, presence of extrapulmonary TB ,sex and BMI were factors associated with anemia after ininitation of highlyactive antiretroviral therapy. Conclusion: Immunohematological profile of the patients has improved after initiation ofhighly active antiretroviral therapy. Treatment interruption, presence of extra pulmonary TB,female sex and Body mass index are factors associated with anemia. Early initiation of highlyactive antiretroviral therapy is helpful in decreasing hematological abnormalities in HIVinfected patients.